Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

57.00 +0.23 (+0.41%)
Official Closing Price Updated: 7:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
89 90 Next >
News headline image
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook ↗
Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblozyl, Camzyos, and Breyanzi. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year... 
Via StockStory
News headline image
Bristol Myers Squibb Co (NYSE:BMY) Q3 2025 Earnings Beat Estimates ↗
Bristol Myers Squibb Q3 2025 earnings beat estimates with $1.63 EPS and $12.22B revenue, driven by strong new product sales. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
Bristol Myers Squibb To Acquire Orbital Therapeutics In $1.5B Deal ↗
Via Stocktwits
News headline image
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025 ↗
Via Stocktwits
News headline image
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
What to Expect from Bristol-Myers Squibb's Earnings ↗
 
Via Benzinga
News headline image
Bristol-Myers Squibb (BMY) To Report Earnings Tomorrow: Here Is What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Dividend-Paying Drug Stocks to Buy at a Discount ↗
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
From Bristol Myers Squibb
Via Business Wire
News headline image
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal ↗
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
Via Benzinga
News headline image
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
News headline image
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks ↗
Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through. 
Via The Motley Fool
Topics Workforce
News headline image
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
News headline image
Why Replimune Stock Was Soaring Today ↗
An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks. 
Via The Motley Fool
News headline image
2 High-Yield Dividend Stocks Too Cheap to Ignore ↗
They are both yielding above 5%. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
3 S&P 500 Stocks We Find Risky
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy? ↗
All of the top 20 drugmakers have a subscription with this software business. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
From Bristol Myers Squibb
Via Business Wire
News headline image
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition ↗
Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion, expanding its RNA and in vivo CAR T-cell therapy portfolio. 
Via Benzinga
News headline image
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Value Stocks with Warning Signs
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a High Dividend Yield and Strong Profitability ↗
Bristol Myers Squibb (BMY) offers a high 5.42% dividend yield with strong profitability and a decade of consistent payouts, making it a top stock for income investors. 
Via Chartmill
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.